Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

NCT05648019 is registered in ClinicalTrials.gov with KK Women's and Children's Hospital as lead sponsor.

NCT NCT05648019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05648019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Lead sponsor
KK Women's and Children's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 15, 2022
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, car, large b-cell lymphoma, lymphoblastic leukemia, lymphoblastic leukemia in children, lymphoblastic leukemia, acute adult